BRAF and melanoma: Additionally, in 2015 Weber et al. found that patients treated with nivolumab achieved more objective responses and had fewer toxic effects than advanced melanoma patients who had progressed after ipilimumab or ipilimumab with a BRAF (proto-oncogene B-Raf) inhibitor [10].